Table 1.
Baseline data based on the treatment data presented
| Total group | Sweden | Denmark | Norway | Iceland | p Value | |
| n (patient-years) | 29 715 | 16 901 | 5700 | 6871 | 243 | |
| n (patients) | 8806 | 4138 | 2150 | 2438 | 80 | |
| Gender | <0.01 | |||||
| Male | 4534 (52%) | 2182 (53%) | 1051 (49%) | 1264 (52%) | 37 (47%) | |
| Female | 4270 (48%) | 1956 (47%) | 1099 (51%) | 1174 (48%) | 41 (53%) | |
| Age groups | <0.01 | |||||
| 0–4 years | 273 (3%) | 156 (4%) | 39 (2%) | 75 (3%) | 3 (4%) | |
| 5–9 years | 1948 (22%) | 1111 (27%) | 401 (19%) | 422 (17%) | 14 (17%) | |
| 10–14 years | 6585 (75%) | 2871 (69%) | 1710 (80%) | 1941 (80%) | 63 (79%) | |
| Treatment | <0.01 | |||||
| Pump | 4869 (57%) | 1984 (50%) | 1244 (61%) | 1601 (68%) | 40 (51%) | |
| Pen | 3607 (43%) | 2003 (50%) | 803 (39%) | 762 (32%) | 39 (49%) | |
| Duration* | 5.1 (3.1) | 5.1 (3.0) | 5.2 (3.2) | 5.2 (3.1) | 5.1 (3.0) | 0.46 |
| HbA1c (mmol/mol)* | 65 (13) | 61 (11) | 67 (13) | 71 (14) | 70 (10) | <0.01 |
| HbA1c (%)* | 8.1 (1.2) | 7.7 (1.0) | 8.2 (1.2) | 8.6 (1.3) | 8.5 (0.9) | <0.01 |
| Insulin dose (IU/kg/day)* | 0.89 (0.3) | 0.86 (0.3) | 0.95 (0.3) | 0.89 (0.3) | 0.90 (0.3) | <0.01 |
*Mean±1SD.
HbA1c, hemoglobin A1c.